QuidelOrtho (QDEL) News Today

QuidelOrtho Corporation (NASDAQ: QDEL) faces mixed signals after its third-quarter 2026 results: adjusted earnings beat expectations, but revenue fell short and declined year over year. The sales weakness appears to have weighed on investor sentiment, while planned cost savings and growth in parts of the business offer potential offsets.

• Positive Sentiment: QuidelOrtho reported Q3 earnings of $0.31 per share, above the $0.18 analyst consensus. It also cited growth in laboratory and immunohematology businesses outside China as evidence of underlying strength. Zacks earnings report
• Positive Sentiment: A cost-transformation and restructuring program is expected to generate more than $80 million in annual savings in 2027, potentially supporting profitability. Third-quarter results announcement
• Neutral Sentiment: The company updated and narrowed its full-year 2026 guidance ranges. The reports provided do not specify the revised figures, making the outlook’s net effect difficult to assess. 2026 guidance update
• Negative Sentiment: Revenue was $618.9 million, below the roughly $627.8 million consensus and down 11.6% year over year. EPS also fell from $0.80 a year earlier, despite beating estimates. A post-results report said the stock dropped 10.6%, reflecting concern about the sales decline and miss. Report on sales and stock reaction